[Inhibitors of GPIIb/IIIa platelet receptors].
Acute myocardial ischaemia is nearly always the result of thrombosis of an unstable coronary lesion responsible for activation of platelet aggregation. The inhibition of platelet activation should lead to a decrease in the incidence of acute complications. However, the pathways of activation of platelet aggregation are multiple (nearly 100 pathways have been identified). The activation of the GPIIb/IIIa receptors which contribute to the formation of the fibrin bridge between two platelets represents the final phase of this activation. The anti-GPIIb/IIIa molecules have, therefore, a much more powerful and rapid anti-aggregant effect than classical anti-aggregant drugs which only act on one of the pathways of this activation. Clinical trials with these therapeutic agents in patients with acute coronary syndromes requiring angioplasty, have shown the superiority of these molecules compared with classical treatment. The main result of these clinical trials are presented.